Navigation Links
Neuropathy Association Research Grants Advance the Understanding of Diabetic Neuropathy and Autoimmune Neuropathies
Date:9/22/2009

Dr. Furtado explains, "Besides providing new clues for how the immune system works, this study will help us identify therapeutics that block the development of autoimmune neuropathies."

Thomas H. Brannagan, III, M.D., the Association's medical advisor affirms, "We continue to invest in critical research that builds on our understanding of neuropathy's many forms, hopeful that our investments will lead to more effective treatment and cures."

About Peripheral Neuropathy

Peripheral neuropathy is one of the most common chronic diseases in the U.S., affecting more than 20 million Americans. Neuropathy results from injury to the peripheral nerves--the motor, sensory and autonomic nerves--connecting the spinal cord to the muscles, skin, blood vessels and internal organs. It usually affects the hands and feet, causing weakness, numbness, lack of coordination or pain.

Approximately 30% of neuropathies are "idiopathic," meaning of an unknown cause; 30% are caused by diabetes. Other causes include autoimmune disorders, tumors, heredity, nutritional deficiencies, infections, trauma, and toxins.

About The Neuropathy Association

The Neuropathy Association is the leading national nonprofit organization providing neuropathy patient support and education, advocating for patients' interests, and supporting critical research. The Association has more than 50,000 members and supporters and a nationwide network of 135 patient support groups, 5 chapters, and 12 Neuropathy Centers of Excellence.

For information about peripheral neuropathy and The Neuropathy Association, visit www.neuropathy.org.

Contact Tina Tockarshewsky at (212) 692-0380


'/>"/>
SOURCE The Neuropathy Association
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Neuropathy Patients, Doctors and Medical Professionals Rally in Sacramento to Demand Access to Lifesaving Medical Treatments
2. First-Time National Poll Confirms Neuropathy Hits Millions in Their Prime
3. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
4. Gene Therapy Improves Diabetic Neuropathy in Study
5. "Electric Socks" for Neuropathy??
6. ReBuilder Medical (RBRM) Neuropathy Market Doubles to $5 Billion
7. Doctors Issue New Neuropathy Test Guidelines
8. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
9. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
10. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
11. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2012)... May 15 (HealthDay News) -- "Team-based care" should be ... Task Force on Community Preventive Services recommended on Tuesday. ... 77 studies that showed improvements in patients, control of ... of health professionals -- a primary care doctor supported ... health worker -- rather than a primary care doctor ...
(Date:5/15/2012)... DETROIT Patients who undergo radical surgery for ... if they,re treated in accredited teaching hospitals with ... also have medical fellowships, according to a new ... which evaluated postoperative complications in 47,100 radical prostatectomy ... those with fewer complications after the surgery were ...
(Date:5/15/2012)... undergo one of the most common treatments for prostate ... to new research by Henry Ford Hospital. , In ... of the surgeon doing the procedure mattered somewhat less ... data gathered throughout the U.S., will be presented this ... Atlanta. , It is both intuitive "practice makes ...
(Date:5/15/2012)... than men after surgical removal of part or all ... dying in the hospital, although they are more likely ... , But Henry Ford Hospital researchers who documented these ... results of the new study, based on population samples ... at the American Urological Association,s Annual Meeting in Atlanta. ...
(Date:5/15/2012)... a team of Rice University freshmen took a mousetrap ... children in the developing world. , "The goal was ... so we could prevent over-hydration and under-hydration," said Melissa ... in Pediatrics) team and a mechanical engineering major. "It,s ... the world, where conditions can be pretty primitive and ...
Breaking Medicine News(10 mins):Health News:U.S. Task Force Issues Blood Pressure Guidelines 2Health News:Fewer prostate cancer surgery complications found in teaching hospitals with fellowship programs 2Health News:Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery 2Health News:Women fare better than men, but need more blood after kidney cancer surgery 2Health News:Women fare better than men, but need more blood after kidney cancer surgery 3Health News:This 'mousetrap' may save lives 2
... the third phase of clinical trail conducted by researchers at ... weekly dose of erythropoietin //(EPO) is a very effective treatment ... ,EPO is a natural hormone that stimulates production ... cell (RBC) transfusions in these children. This is the ...
... in New York City has discovered that chronic pain occurs ... his colleagues were studying chronic pain at the molecular and ... occurs and the neurons becomes excited and begin to send ... when the stimulus is removed the nerves become dormant and ...
... exchange agreement with an Israeli company to introduce its ... technology enabled patients to be monitored anywhere and at ... telephones, Heartline Managing Director Dr Selva Annamalai told reporters ... doctor, 24 hours a day from anywhere, who could ...
... condition, chronic widespread pain is often difficult to ... depression and poor sleep.// ,A link between ... FM like symptoms after treatment with cytokine interleukin ... contradictory results. A new study published in the ...
... Cambodia in the Aids prevention initiatives have been applauded, ... of condoms.// ,Professor K. Satkunantham, the director of ... 100 per cent condom use programmes in Thailand and ... ,In the 25 years of the existence ...
... French teenage girl was admitted appearing unsteady and mentally sluggish ... doctors. // ,In addition it was found that the ... were puzzled because there appeared to be no family history ... in this week's New England Journal of Medicine. ...
Other Medicine News:Health News:EPO Effective For Cancer Patients Suffering From Anemia 2Health News:Insufficent Anti-inflammatoy Proteins Leads to Chronic Pain 2Health News:Teens High on Mothballs 2
(Date:5/15/2012)... -- PLC Systems Inc. (OTCBB: PLCSF), a company focused ... results for the three-month period ended March 31, ... operations, since PLC completed the sale of its ... the first quarter of 2011.  Results from the ... all periods presented. First quarter 2012 ...
(Date:5/15/2012)... 15, 2012 BiO2 Medical, Inc. a ... in San Antonio, Texas, and R&D and manufacturing ... has received CE Mark approval for the Angel™ ... permanently attached to a central venous catheter (CVC) ... in critically ill patients. This novel IVC filter/CVC ...
(Date:5/15/2012)... May 15, 2012  Boston Scientific Corporation ... the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium ... treating de novo coronary artery ... PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent System ...  The trial reported one-year clinical and six-month ...
Breaking Medicine Technology:PLC Systems Reports First Quarter 2012 Results 2PLC Systems Reports First Quarter 2012 Results 3PLC Systems Reports First Quarter 2012 Results 4PLC Systems Reports First Quarter 2012 Results 5PLC Systems Reports First Quarter 2012 Results 6One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6Cyberonics to Present at JMP Securities 4th Annual Healthcare Focus Conference 14268 1Cyberonics to Present at JMP Securities 4th Annual Healthcare Focus Conference 14268 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 1Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 1Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 2Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 3Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 5Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 6Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 7Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 8Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 9Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 10Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 11Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 12Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 13Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 14Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 15Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 16Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 17
... Presented at International Conference on Malignant ... Shows Dose Dependent Single Agent Activity, BETHESDA, ... biopharmaceutical company developing novel, proprietary antibodies,for the treatment ... update of an ongoing phase 1 clinical trial ...
... Discuss Clinical, Financial ... DUBLIN, Ohio, June 4 In a move that ... of,hospital-acquired infections (HAIs), Cardinal Health announced today that,it will ... will focus on the leadership and operational issues that ...
Other Medicine Technology:Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 2Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 3Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 4Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 5Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 2Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 3Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 4
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ... tip style, size and angle required for ...
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
Medicine Products: